Jenny Fielding offers $100K check to Finecto conditional on round completion
Jenny Fielding · How Latin American Founders Keep Their Deals Alive · Sep 24, 2025 · at 19:18
Jenny Fielding of Everywhere Ventures extends an investment offer to Ariel Puga, founder of Finecto.
0:00 / 0:16exact quote · 16.8s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“So with that, we are interested in a hundred K check. However, we would want the whole round to come together. So maybe slightly different than some of your other investors that kind of invest along the way. We would want to make sure that you're adequately capitalized.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Jenny Fielding
Fielding: $350 annual per-user employer fee is unseen in B2B software
“For healthcare, I haven't seen it for software.”
Fielding: Enterprise procurement is where software deals go to die
“Over the last decade of me investing, I've heard the procurement pitch many times. It's kind of where deals go to die. Everyone hates it. Many people have tried to have SaaS companies around this or SaaS solutions.”
Fielding: Finecto's exit paths include regional banks and LatAm software providers
“I feel like a bank could buy him, you know, the SAP of LATAM can buy him. So it seems like there are some exit opportunities”
Fielding: Everywhere Ventures Will Not Invest at $12M Valuation
“So we wouldn't invest at a 12, but as the round comes together, we would be interested.”
Fielding: Levee's fundraising round will not close quickly
“My bad is that this round is not going to come together super quickly, and you're going to get a few more months of data from that big hotel that you can kind of base your decisions on.”
Jenny Fielding passes on Curie DX over multi-model approach and FDA complexity
“I think with multiple business models, a four million dollar raise, which is, you know, quite high for me as a pre-seed, and the FDA path, I think that's going to be just a complicated one for me to get my head around, so I think I'm out.”